CGT Commercialization:
Tackling Barriers to Market Success

Cell and gene therapies are growing rapidly, with FDA approvals at record highs and investment surging 30% to $15.2 billion. These transformative treatments offer hope for incurable conditions but face unique manufacturing, logistics, and administration challenges that can limit patient access.

This report explores six cutting-edge CGT innovations—from the first solid tumor cell therapy to personalized cancer vaccines—highlighting barriers to patient reach. Through case studies and expert insights, it offers strategies to address access, supply chain, and regulatory hurdles critical for commercial success. Explore:

• Analysis of breakthrough therapies like TECELRA, ENCELTO, and rare disease treatments
• Commercialization challenges and solutions for autologous vs. allogeneic therapies
• Strategic guidance for managing logistics, patient identification, and provider education

​